Aldeyra Therapeutics Inc

ALDX remains in an early/fragile Stage 1 consolidation base with accumulation signals from follow-through and exhaustion tags. Medium-term bias is bullish given the flattening 9/21 EMA regime and bottoming patterns, but price recently extended into resistance and is now pulling back. Short-term timing is neutral, so execution is deferred—stalking for pullbacks into the 9/21 EMA support zone.

• ↑Phase III Reproxilab trial achieved p=0.002 reduction in ocular discomfort.
• ↑Cash and marketable securities totaled $174.3M as of Dec 31, covering expenses until mid-2024.
• ↓Net loss of $62M in 2022 increased from $57.8M prior year.